Skip to main content
Clinical Trials/JPRN-jRCTs031200124
JPRN-jRCTs031200124
Completed
未知

Study on the use of Convalescent plasma therapy as a COVID-19 treatment - Study on the use of Convalescent plasma therapy as a COVID-19 treatment

Saito Sho0 sites11 target enrollmentSeptember 17, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
COVID-19, Coronavirus disease
Sponsor
Saito Sho
Enrollment
11
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The study was terminated; the analysis originally planned was not performed. The study was terminated in accordance with the recommendation of the Efficacy and Safety Evaluation Committee. However, this does not negate the assumption: "The rate of intubation in the existing treatment is assumed to be 25%, and this rate should be reduced by more than half (i.e., to 12% or less).

Registry
who.int
Start Date
September 17, 2020
End Date
March 18, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Saito Sho

Eligibility Criteria

Inclusion Criteria

  • 1\) Written consent obtained from the patient or his/her legal representative.
  • 2\) COVID\-19 diagnosed by PCR, LAMP, etc. and was admitted.
  • 3\) Patients who satisfy the following at admission: A) SpO2 \<\= 94% or B) require supplimental oxygen.
  • 4\) 20 years or older at enrollment

Exclusion Criteria

  • 1\) Pregnant or breastfeeding at enrollment
  • 2\) Unable to conduct blood transfusion due to religious reasons
  • 3\) Enrolled in other COVID\-19 intervension study
  • 4\) Previously administered with COVID\-19 convalescent plasma
  • 5\) Known allergy to blood products
  • 6\) Deficiency of plasma protein, such as IgA
  • 7\) Not appropriate to enroll determined by the PI for other reasons

Outcomes

Primary Outcomes

Not specified

Similar Trials